Sanofi SA has reported data from a Phase 2 trial of a Janus Kinase 2 (JAK2) inhibitor in myelofibrosis which showed the therapy achieved reductions in spleen size and other disease symptoms in 31 randomised patients. ---Subscribe to MedNous to access this article--- Clinical Research Company News
